Lilly’s retatrutide shows substantial weight loss and A1C reduction
Lilly’s triple agonist retatrutide delivered substantial weight loss and A1C reduction, underscoring potential promise for people with obesity and type 2 diabetes.
Lilly’s triple agonist retatrutide delivered substantial weight loss and A1C reduction, underscoring potential promise for people with obesity and type 2 diabetes.